Piper Jaffray analyst Matt O'Brien says shares of ZELTIQ Aesthetics (ZLTQ ) could be volatile around Cynosure's (CYNO) upcoming competitive body contouring launch during its analyst meeting on September 15. O'Brien does not expect the launch of a competing product to impact ZELTIQ's ability to meet or beat numbers in the coming years, however, as his channel checks indicate Cynosure's system is painful and needs energy modulation. Further, the analyst views the body contouring market as a $4B opportunity that is large enough for multiple players. He recommends buying shares of ZELTIQ on any weakness and reiterates an Overweight rating on the name with a $40 price target.